In contrast to the parental tumors which exhibited high sensitivity to TKI treatments, the FOXA1-knockout tumors displayed 10%–30% tumor growth and maintained higher expression of squamous markers upon drug treatments, indicating that FOXA1 knockout at least partially conferred TKI resistance (Fig. 4D–G and Fig. S8F–K). The gene discussed is FOXA1; the disease is neoplasm.